keyword
MENU ▼
Read by QxMD icon Read
search

MDR Tuberculosis

keyword
https://www.readbyqxmd.com/read/28210505/nanotechnology-based-approach-in-tuberculosis-treatment
#1
REVIEW
Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das
Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment...
2017: Tuberculosis Research and Treatment
https://www.readbyqxmd.com/read/28202091/isolation-unit-for-multidrug-resistant-tuberculosis-patients-in-a-low-endemic-country-a-step-towards-the-world-health-organization-end-tb-strategy
#2
M C Payen, J P VAN Vooren, O Vandenberg, N Clumeck, S DE Wit
Tuberculosis (TB) remains a threat to public health and is the second cause of death due to a single infectious agent after HIV/AIDS. The worldwide distribution of TB is heterogeneous. The incidence is decreasing in most high-income regions, but the situation remains worrying in many parts of the world. The emergence of Mycobacterium tuberculosis strains resistant to key agents used in treatment (rifampin and isoniazid) contributes to TB transmission around the world. To achieve TB elimination, both high and low endemic countries must upscale their efforts to decrease disease transmission and improve cure rates...
February 16, 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28201993/structure-and-variation-of-crispr-and-crispr-flanking-regions-in-deleted-direct-repeat-region-mycobacterium-tuberculosis-complex-strains
#3
Paul Jeffrey Freidlin, Israel Nissan, Anna Luria, Drora Goldblatt, Lana Schaffer, Hasia Kaidar-Shwartz, Daniel Chemtob, Zeev Dveyrin, Steven Robert Head, Efrat Rorman
BACKGROUND: CRISPR and CRISPR-flanking genomic regions are important for molecular epidemiology of Mycobacterium tuberculosis complex (MTBC) strains, and potentially for adaptive immunity to phage and plasmid DNA, and endogenous roles in the bacterium. Genotyping in the Israel National Mycobacterium Reference Center Tel-Aviv of over 1500 MTBC strains from 2008-2013 showed three strains with validated negative 43-spacer spoligotypes, that is, with putatively deleted direct repeat regions (deleted-DR/CRISPR regions)...
February 15, 2017: BMC Genomics
https://www.readbyqxmd.com/read/28199375/has-universal-screening-with-xpert%C3%A2-mtb-rif-increased-the-proportion-of-multidrug-resistant-tuberculosis-cases-diagnosed-in-a-routine-operational-setting
#4
Pren Naidoo, Rory Dunbar, Judy Caldwell, Carl Lombard, Nulda Beyers
SETTING: Primary health services in Cape Town, South Africa where the introduction of Xpert® MTB/RIF (Xpert) enabled simultaneous screening for tuberculosis (TB) and drug susceptibility in all presumptive cases. STUDY AIM: To compare the proportion of TB cases with drug susceptibility tests undertaken and multidrug-resistant tuberculosis (MDR-TB) diagnosed pre-treatment and during the course of 1st line treatment in the previous smear/culture and the newly introduced Xpert-based algorithms...
2017: PloS One
https://www.readbyqxmd.com/read/28197340/phenotypic-and-genotypic-analysis-of-multidrug-resistant-mycobacterium-tuberculosis-isolates-from-sudanese-patients
#5
Solima M A Sabeel, Mohamed Ahmed Salih, Manasik Ali, Salah-Eldin El-Zaki, Nadir Abuzeid, Zeinab Abubaker Mohammed Elgadi, Hisham N Altayb, Asrar M A Elegail, Nuha Y Ibrahim, Bahaeldin K Elamin
Background. Currently, mutations in rpoB, KatG, and rrs genes and inhA promoter were considered to be involved in conferring resistance to rifampicin, isoniazid, and streptomycin in Mycobacterium tuberculosis (MTB). Objective. The aims of this study were to detect the prevalence of first-line tuberculosis (TB) drug resistance among a group of previously treated and newly detected TB patients, to determine the association between prevalence of multidrug resistance (MDR) and demographic information (age and sex), to explain genes correlated with MDR Mycobacterium tuberculosis, and to characterize MTB via 16S ribosomal RNA (16S rRNA) analysis...
2017: Tuberculosis Research and Treatment
https://www.readbyqxmd.com/read/28182726/spatial-patterns-of-multidrug-resistant-tuberculosis-and-relationships-to-socio-economic-demographic-and-household-factors-in-northwest-ethiopia
#6
Kefyalew Addis Alene, Kerri Viney, Emma S McBryde, Archie C A Clements
BACKGROUND: Understanding the geographical distribution of multidrug-resistant tuberculosis (MDR-TB) in high TB burden countries such as Ethiopia is crucial for effective control of TB epidemics in these countries, and thus globally. We present the first spatial analysis of multidrug resistant tuberculosis, and its relationship to socio-economic, demographic and household factors in northwest Ethiopia. METHODS: An ecological study was conducted using data on patients diagnosed with MDR-TB at the University of Gondar Hospital MDR-TB treatment centre, for the period 2010 to 2015...
2017: PloS One
https://www.readbyqxmd.com/read/28182570/long-term-outcome-and-safety-of-prolonged-bedaquiline-treatment-for-multidrug-resistant-tuberculosis
#7
Lorenzo Guglielmetti, Marie Jaspard, Damien Le Dû, Marie Lachâtre, Dhiba Marigot-Outtandy, Christine Bernard, Nicolas Veziris, Jérôme Robert, Yazdan Yazdanpanah, Eric Caumes, Mathilde Fréchet-Jachym
Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients treated with this drug outside clinical trials.All MDR-TB patients who started treatment from January 1, 2011 to December 31, 2013 and received ≥30 days of bedaquiline were included in a multicentre observational cohort.Among 45 MDR-TB patients, 53% harboured isolates resistant to both fluoroquinolones and second-line injectables, and 38% harboured isolates resistant to one of these drug classes...
December 22, 2016: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28178199/combined-use-of-delamanid-and-bedaquiline-to-treat-multidrug-resistant-and-extensively-drug-resistant-tuberculosis-a-systematic-review
#8
REVIEW
Giovanni Battista Migliori, Emanuele Pontali, Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Simon Tiberi, Marina Tadolini, Susanna Esposito
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline used in combination. A search of peer-reviewed, scientific evidence was carried out, aimed at evaluating the efficacy/effectiveness, safety, and tolerability of delamanid and bedaquiline-containing regimens in individuals with pulmonary/extrapulmonary disease, which were bacteriologically confirmed as M/XDR-TB...
February 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28173763/risk-factors-for-poor-multidrug-resistant-tuberculosis-treatment-outcomes-in-kyiv-oblast-ukraine
#9
Omowunmi Aibana, Mariya Bachmaha, Viatcheslav Krasiuk, Natasha Rybak, Timothy P Flanigan, Vasyl Petrenko, Megan B Murray
BACKGROUND: Ukraine is among ten countries with the highest burden of multidrug- resistant TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below global success rates as reported by the World Health Organization. Few studies have evaluated predictors of poor MDR-TB outcomes in Ukraine. METHODS: We conducted a retrospective analysis of patients initiated on MDR-TB treatment in the Kyiv Oblast of Ukraine between January 01, 2012 and March 31st, 2015...
February 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28166377/multidrug-resistant-tuberculosis-in-transplant-recipients-case-report-and-review-of-the-literature
#10
Moises A Huaman, Robert Brawley, David Ashkin
Transplant recipients are at increased risk of tuberculosis (TB). We describe a case of pulmonary and vertebral multidrug-resistant TB (MDR-TB) in a kidney transplant patient who required neurosurgical intervention and unfortunately developed fatal nosocomial complications. Thirteen transplant recipients with MDR-TB were previously reported in the literature (1 hematopoietic cell transplant, 1 heart transplant, 1 lung transplant, 1 heart-lung ransplant, and 9 kidney transplant recipients). Extrapulmonary disease, severe treatment complications, and deaths were observed in patients who developed MDR-TB after transplantation...
February 6, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28163165/the-risk-of-global-epidemic-replacement-with-drug-resistant-m-tuberculosis-strains
#11
REVIEW
Emma S McBryde, Michael T Meehan, Tan N Doan, Romain Ragonnet, Ben J Marais, Vanina Guernier, James M Trauer
OBJECTIVES: Multi-drug resistant tuberculosis (MDR-TB) is a threat to TB control. To guide TB control, it is essential to understand the extent to which and the circumstances in which MDR-TB will replace drug-susceptible TB (DS-TB) as the dominant phenotype. We examined the issue by presenting evidence from genomics, pharmacokinetics and epidemiology studies. We then synthesised this evidence into a mathematical model. METHODS: Our model consider two TB strains, one with and one without MDR phenotype...
February 2, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28162983/activity-of-moxifloxacin-and-linezolid-against-mycobacterium-tuberculosis-in-combination-with-potentiator-drugs-verapamil-timcodar-colistin-and-sq109
#12
Gerjo J de Knegt, Aart van der Meijden, Corné P de Vogel, Rob E Aarnoutse, Jurriaan E M de Steenwinkel
Current treatment for tuberculosis (TB) is complicated by the emergence of multidrug resistant TB (MDR-TB). As a result, there is an urgent need for new powerful anti-TB regimens and novel strategies. In this study, we aimed to potentiate a moxifloxacin + linezolid backbone as treatment for MDR-TB with the efflux pump inhibitors verapamil and timcodar as well as with drugs that act on mycobacterial cell wall stability such as colistin and SQ109. Using a time-kill kinetics assay, the activities of moxifloxacin, linezolid, verapamil, timcodar, colistin and SQ109 as single drugs against Mycobacterium tuberculosis were evaluated...
February 2, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28157461/multidrug-resistant-tuberculosis-patients-views-of-interventions-to-reduce-treatment-loss-to-follow-up
#13
T Tupasi, A M C G Garfin, J M Mangan, R Orillaza-Chi, L C Naval, G I Balane, R Basilio, A Golubkov, E S Joson, W-J Lew, V Lofranco, M Mantala, S Pancho, J N Sarol, A Blumberg, D Burt, E V Kurbatova
SETTING: Patients who initiated treatment for multidrug-resistant tuberculosis (MDR-TB) at 15 Programmatic Management of Drug-resistant Tuberculosis (PMDT) health facilities in the Philippines between July and December 2012. OBJECTIVES: To describe patients' views of current interventions, and suggest changes likely to reduce MDR-TB loss to follow-up. METHODS: In-depth interviews were conducted between April and July 2014 with MDR-TB patients who were undergoing treatment, had finished treatment at the time of the interview (controls), or had been lost to follow-up (LTFU)...
January 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28157460/anti-tuberculosis-drug-resistance-in-ethiopia-systematic-review
#14
S Weldegebreal, T Mebrahtu
BACKGROUND: Resistance to anti-tuberculosis drugs threatens to undermine effective control of tuberculosis (TB). In areas with weak TB control and misuse of anti-tuberculosis drugs, hotspots of multidrug-resistant TB (MDR-TB) have appeared. The aim of this review is to determine the prevalence rate of any anti-tuberculosis drug resistance, monoresistance and MDR-TB in Ethiopia. METHODS: A systematic review of the literature on any resistance, monoresistance and MDR-TB was conducted...
January 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28157459/multidrug-resistant-tuberculosis-in-bangladesh-results-from-a-sentinel-surveillance-system
#15
S Banu, M T Rahman, S Ahmed, R Khatun, S S Ferdous, B Hosen, M M Rahman, T Ahmed, J S Cavanaugh, J D Heffelfinger
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is a serious obstacle to successful TB control. The 2010-2011 Bangladesh Drug Resistance Survey (DRS) showed MDR-TB prevalence to be 7% overall, 1.4% in new and 28.5% in previously treated patients. We aimed to determine the rate of MDR-TB in selected sentinel sites in Bangladesh. METHODS: Fourteen hospitals from the seven divisions in Bangladesh were selected as sentinel surveillance sites. Newly registered TB patients were systematically enrolled from August 2011 to December 2014...
January 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28157458/estimating-the-global-burden-of-multidrug-resistant-tuberculosis-among-prevalent-cases-of-tuberculosis
#16
S Nourzad, H E Jenkins, M Milstein, C D Mitnick
BACKGROUND: Estimates of the multidrug-resistant tuberculosis (MDR-TB) burden are based on incomplete, infrequently updated data among a limited pool of notified or incident pulmonary TB cases. METHODS: Using World Health Organization data reported by 217 countries/territories in 2014, we calculated the MDR-TB burden among prevalent TB cases and compared these with estimates among incident and notified TB patients. We also compared treatment coverage across estimates...
January 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28155306/an-audiological-profile-of-patients-infected-with-multi-drug-resistant-tuberculosis-at-a-district-hospital-in-kwazulu-natal
#17
Delicia Appana, Lavanithum Joseph, Jessica Paken
BACKGROUND: The increased incidence of multi-drug-resistant tuberculosis (MDR-TB) and the consequent use of aminoglycosides with their ototoxic potential necessitate a better understanding of the audiological pattern of infected patients. OBJECTIVE: To describe the occurrence and nature of hearing loss in patients with MDR-TB receiving aminoglycosides over a period of 6 months. METHODS: Baseline and five consecutive monthly audiological assessments were conducted on 52 adults at a hospital in KwaZulu-Natal...
November 25, 2016: South African Journal of Communication Disorders. die Suid-Afrikaanse Tydskrif Vir Kommunikasieafwykings
https://www.readbyqxmd.com/read/28142116/a-novel-benzothiazinethione-analogue-sklb-tb1001-displays-potent-antimycobacterial-activities-in-a-series-of-murine-models
#18
Chao Gao, Ting-Hong Ye, Cui-Ting Peng, Yao-Jie Shi, Xin-Yu You, Lu Xiong, Kai Ran, Li-Dan Zhang, Xiu-Xiu Zeng, Ning-Yu Wang, Luo-Ting Yu, Yu-Quan Wei
New chemotherapeutic compounds and regimens are needed to combat multidrug-resistant Mycobacterium tuberculosis. Here, we used a series of murine models to assess an antitubercular lead compound SKLB-TB1001. In the Mycobacterium bovis bacillus Calmette-Guérin and the acute M. tuberculosis H37Rv infection mouse models, SKLB-TB1001 significantly attenuated the mycobacterial load in lungs and spleens. The colony forming unit counts and histological examination of lungs from H37Rv infected mice revealed that the benzothiazinethione analogue SKLB-TB1001 as a higher dose level was as effective as isoniazid...
January 28, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28141813/determination-of-plasma-concentrations-of-levofloxacin-by-high-performance-liquid-chromatography-for-use-at-a-multidrug-resistant-tuberculosis-hospital-in-tanzania
#19
Andrew Ebers, Suzanne Stroup, Stellah Mpagama, Riziki Kisonga, Isaack Lekule, Jie Liu, Scott Heysell
Therapeutic drug monitoring may improve multidrug-resistant tuberculosis (MDR-TB) treatment outcomes. Levofloxacin demonstrates significant individual pharmacokinetic variability. Thus, we sought to develop and validate a high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection for levofloxacin in patients on MDR-TB treatment. The HPLC-UV method is based on a solid phase extraction (SPE) and a direct injection into the HPLC system. The limit of quantification was 0.25 μg/mL, and the assay was linear over the concentration range of 0...
2017: PloS One
https://www.readbyqxmd.com/read/28137814/pharmacokinetic-modeling-and-limited-sampling-strategies-based-on-healthy-volunteers-for-monitoring-of-ertapenem-in-mdr-tb-patients
#20
S P van Rijn, M A Zuur, R van Altena, O W Akkerman, J H Proost, W C M de Lange, H A M Kerstjens, D J Touw, T S van der Werf, J G W Kosterink, J W C Alffenaar
BACKGROUND: Ertapenem is a broad spectrum carbapenem antibiotic and is being explored against Mycobacterium tuberculosis Carbapenems have anti-bacterial activity when the plasma concentration exceeds the minimal inhibitory concentration at least 40% of the time (40%T>MIC). To assess 40%T>MIC in multidrug-resistant tuberculosis (MDR-TB) patients, a limited sampling strategy was developed using a population pharmacokinetic model based on healthy volunteers. METHODS: A two-compartment population pharmacokinetic model was developed from data in forty-two healthy volunteers, using an iterative two-stage Bayesian method...
January 30, 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
70929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"